EUVIMEDEUVIMED entdecken
Crossref

A fluorescent choline kinase alpha inhibitor for intraoperative molecular imaging during resection of canine NSCLC tumors

Sofya A Osharovich iD, David E Holt, Michael C Hart iD, Ritesh K Isuri iD, Jennifer L Huck iD, Stefan Harmsen iD, Charles-Antoine Assenmacher iD, Enrico Radaelli iD, Sean Carlin, Alex C Watts iD, Maureen A Griffin iD, Heather Scavello iD und 4 weitere

Science Translational Medicine · 2026

DOI: 10.1126/scitranslmed.aea4947 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, 2026. Verfasst von Sofya A Osharovich und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. Hauptthemen laut MEDLINE: Lung Neoplasms, Choline Kinase, Molecular Imaging, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 56 Literaturangaben. Gefördert von: National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Choline kinase α (ChoKα) is a biomarker of lung cancer, is overexpressed in 60% of human pulmonary malignancies, and is associated with an aggressive phenotype and poor clinical outcome. Patients with lung cancer who undergo surgery have a recurrence rate of 30 to 50%, indicating a potential need for better tumor detection modalities. A near-infrared fluorescent ChoKα-targeting imaging agent, JAS239 (λ ex , λ em : 745, 775 nanometers), was developed for intraoperative identification of tumors, their margins, and local metastases. In lung cancer cells, JAS239 inhibited phosphocholine production, reduced viability in a dose-dependent manner, and accumulated in the cytoplasm where ChoKα is active. JAS239 had favorable pharmacokinetics and pharmacodynamics for imaging metastatic lung lesions in mice. In situ and ex vivo fluorescence imaging of primary lung tumors in a canine clinical trial showed distinct tumor identification and margin delineation with a tumor-to-background ratio of 5.0 ± 0.6 and a contrast-to-variance ratio of 2.0 ± 0.2 at 0.5 milligram/kilogram. Fluorescence imaging identified a clinically significant event where an occult lesion was found after primary tumor resection. Fluorescence imaging also identified a close surgical margin, which prompted further investigation. Immunohistochemistry for ChoKα showed overexpression in canine lung tumors proportional to tumor fluorescence. Ex vivo human tumor painting demonstrated preferential JAS239 localization with a tumor-to-background ratio of 1.5 ± 0.1 and a contrast-to-variance ratio of 0.9 ± 0.1. These studies establish JAS239 as a safe and effective imaging agent for intraoperative lung tumor detection, warranting further evaluation for human patients with lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCholine KinaseMolecular ImagingCarcinoma, Non-Small-Cell LungEnzyme InhibitorsFluorescent DyesAnimalsDogsCell Line, TumorHumansFemaleMice

Substanzen

Choline KinaseEnzyme InhibitorsFluorescent Dyes

Autor:innen und Institutionen

  • Department of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
  • Department of Clinical Sciences and Advanced Medicine, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA 19104, USA.
  • Department of Chemistry, University of Pennsylvania, School of Arts and Sciences, Philadelphia, PA 19104, USA.
  • Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA 19104, USA.
  • Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
  • Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.

ORCID-Profile: Sofya A Osharovich, Michael C Hart, Ritesh K Isuri, Jennifer L Huck, Stefan Harmsen, Charles-Antoine Assenmacher, Enrico Radaelli, Alex C Watts, Maureen A Griffin, Heather Scavello, Wei-Ting Hwang, Anatoliy V Popov, Sunil Singhal, Edward J Delikatny

Förderung

  • National Institutes of Health

Zitieren

APA

Osharovich, S. A., Holt, D. E., Hart, M. C., Isuri, R. K., Huck, J. L., Harmsen, S., Assenmacher, C. A., Radaelli, E., Carlin, S., Watts, A. C., Griffin, M. A., Scavello, H., Hwang, W. T., Popov, A. V., Singhal, S., & Delikatny, E. J. (2026). A fluorescent choline kinase alpha inhibitor for intraoperative molecular imaging during resection of canine NSCLC tumors. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aea4947

Vancouver

Osharovich SA, Holt DE, Hart MC, Isuri RK, Huck JL, Harmsen S, et al. A fluorescent choline kinase alpha inhibitor for intraoperative molecular imaging during resection of canine NSCLC tumors. Science Translational Medicine. 2026. doi:10.1126/scitranslmed.aea4947

BibTeX
@article{Osharovich2026,
  author = {Osharovich, Sofya A and Holt, David E and Hart, Michael C and Isuri, Ritesh K and Huck, Jennifer L and Harmsen, Stefan and Assenmacher, Charles-Antoine and Radaelli, Enrico and Carlin, Sean and Watts, Alex C and Griffin, Maureen A and Scavello, Heather and Hwang, Wei-Ting and Popov, Anatoliy V and Singhal, Sunil and Delikatny, Edward J},
  title = {A fluorescent choline kinase alpha inhibitor for intraoperative molecular imaging during resection of canine NSCLC tumors},
  journal = {Science Translational Medicine},
  year = {2026},
  doi = {10.1126/scitranslmed.aea4947}
}
Kostenlos starten →